- Home
- TCRX vs DXR Comparison
TCRX vs DXR Comparison
Compare TCRX & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | DXR |
|---|---|---|
| Founded | 2018 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 59.0M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TCRX | DXR |
|---|---|---|
| Price | $0.75 | $10.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 311.4K | 2.2K |
| Earning Date | 05-08-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | $19.81 | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.72 | $8.56 |
| 52 Week High | $2.57 | $14.76 |
Technical Indicators
Market Signals| Indicator | TCRX | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 38.46 |
| Support Level | $0.73 | $9.64 |
| Resistance Level | $0.82 | $11.16 |
| Average True Range (ATR) | 0.04 | 0.25 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 9.48 | 8.30 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.